Target intelligence / Profile preview

MSC antisense RNA 1 (MSC-AS1)

Target: MSC-AS1
Molecular classification: Long non-coding RNA (lncRNA), Antisense RNA

Overview

MSC antisense RNA 1 (MSC-AS1) is a long non-coding RNA (lncRNA) classified as an antisense transcript, transcribed from the opposite strand of a protein-coding gene. It functions primarily in gene regulation, including modulation of chromatin state and gene transcription through epigenetic mechanisms such as histone modification. MSC-AS1 can act as a competing endogenous RNA by binding microRNAs, thereby influencing the expression of downstream mRNAs. Its dysregulation has been associated with cancer pathogenesis, including uveal melanoma and prostate cancer, where its expression and methylation status can serve as a prognostic biomarker. There are no known drugs specifically targeting this lncRNA, and it is not considered a conventional drug target like enzymes or receptors.

Other names: MAT1MSC-antisense-transcript 1

Biological functions

Regulation of gene expressionEpigenetic regulation (influencing histone modification, e.g., H3K4 trimethylation)Competing endogenous RNA (ceRNA) activity (miRNA sponging)Involvement in RNA binding, cytochrome-c-oxidase activity, ATP binding, kinase activity, oxidoreductase activity, translation initiation, cadherin binding

Disease associations

Cancer (including uveal melanoma, prostate cancer, clear cell renal cell carcinoma)Episodic pain syndrome, familial, 1

Biomarkers

Prognostic biomarker in prostate cancer (hypermethylation and lower expression associated with poor prognosis)

Beyond the preview

Go deeper on MSC antisense RNA 1 (MSC-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSC antisense RNA 1 (MSC-AS1).

Explore the full profile